Myelofibrosis

Imago BioSciences Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis 

Retrieved on: 
Thursday, July 30, 2020
Oncology, Health, Other Science, Clinical trials, Science, Pharmaceutical, Biotechnology, Myelofibrosis, KDM1A, Cancer, IMG-7289 (Bomedemstat), Imago BioSciences

To be eligible for PRIME, a medicine must address an unmet medical need and show potential clinical benefit based on early trial data.

Key Points: 
  • To be eligible for PRIME, a medicine must address an unmet medical need and show potential clinical benefit based on early trial data.
  • Myelofibrosis is a progressive cancer in which bone marrow is gradually replaced by fibrous, scar-like tissue impairing the production of blood cells for which treatment options are limited.
  • "We are excited to receive PRIME designation for IMG-7289, our first LSD1 inhibitor in the clinic, said Hugh Young Rienhoff, Jr., M.D., CEO of Imago BioSciences.
  • Imago BioSciences is a private clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes.

Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company's Platform for Treating Neurodegenerative Diseases

Retrieved on: 
Wednesday, July 29, 2020
Clinical research, Design of experiments, Myelofibrosis, Placebo-controlled study, Health

The Phase 1 study results presented today support Samus' advancement of PU-AD into its now initiated Phase 2a study in AD, and its upcoming Phase 2a study in ALS expected to initiate later this year.

Key Points: 
  • The Phase 1 study results presented today support Samus' advancement of PU-AD into its now initiated Phase 2a study in AD, and its upcoming Phase 2a study in ALS expected to initiate later this year.
  • "We expect to initiate a Phase 2a study of PU-AD in ALS in the second half of 2020, while we continue to advance our ongoing study in Alzheimer's."
  • The Phase 1 double-blinded, placebo-controlled, single-and multiple-ascending dose study evaluated the safety and pharmacokinetics of PU-AD in healthy volunteers.
  • Samus' lead oncology candidate, orally administered PU-H71, is being evaluated in a Phase 1b study of myelofibrosis in combination with ruxolitinib.

Sierra Oncology Appoints Christina Thomson as General Counsel

Retrieved on: 
Tuesday, July 28, 2020
Nitriles, Tyrosine kinases, Benzamides, Momelotinib, Morpholines, Janus kinase 2, Myelofibrosis, General counsel, Cancer, Clinical medicine, Chemistry

VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointment of Christina Thomson as General Counsel.

Key Points: 
  • VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointment of Christina Thomson as General Counsel.
  • Christina is a highly effective General Counsel with a wealth of business and legal expertise, including corporate and competitive strategy, licensing, and commercialization planning.
  • Christina Thomson is a seasoned legal executive who has served as General Counsel for several public, private and non-profit life sciences companies, including Athira Pharma, Infectious Disease Research Institute, APT Pharmaceuticals and Avigen, in addition to representing clients in private practice.
  • Sierra Oncology granted an equity award on July 28, 2020 to Christina Thomson as a material inducement to her employment as General Counsel with the Company.

Imago BioSciences Provides Update on Preliminary Data for Bomedemstat at the 2020 Virtual EHA Meeting

Retrieved on: 
Friday, June 12, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Life sciences, Articles, Pharmaceutical industry, Pharmacy, Myelofibrosis, Clinical trial, Biopharmaceutical, Bomedemstat (IMG-7289), Imago BioSciences

Imago BioSciences today announced the presentation of data at the 2020 Virtual European Hematology Association (EHA) meeting relating to the clinical trial of bomedemstat (IMG-7289) for the treatment of advanced myelofibrosis.

Key Points: 
  • Imago BioSciences today announced the presentation of data at the 2020 Virtual European Hematology Association (EHA) meeting relating to the clinical trial of bomedemstat (IMG-7289) for the treatment of advanced myelofibrosis.
  • The presentation today as a poster reflects a more extensive analysis of a larger patient population based on a later data cutoff.
  • In this ongoing study, the preliminary data indicate that bomedemstat has significant clinical activity as monotherapy in a myelofibrosis patient population with advanced disease and no therapeutic alternatives.
  • Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes.

Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise

Retrieved on: 
Friday, June 12, 2020
Political spectrum, Left-wing politics, Politics of India, EZH2, Myelofibrosis, Communist Party of India, Hematologic disease

If corroborated in further testing, these data suggest that CPI-0610 could potentially change the treatment paradigm in MF.

Key Points: 
  • If corroborated in further testing, these data suggest that CPI-0610 could potentially change the treatment paradigm in MF.
  • We are excited about the emerging profile of CPI-0610, said Jigar Raythatha, Chief Executive Officer ofConstellation Pharmaceuticals.
  • Our goal is to drive CPI-0610 to registration and to transform the standard of care in myelofibrosis and potentially other hematologic diseases.
  • While we are disappointed with the outcome of this study, we remain committed to EZH2 as an important cancer target and will apply the learnings from ProSTAR to our second-generation EZH2 inhibitor, CPI-0209.

Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610

Retrieved on: 
Thursday, May 28, 2020
Myelofibrosis

The agenda of the event will include:

Key Points: 
  • The agenda of the event will include:
    The event will be webcast live and can be accessed on the Investor Relations section of Constellations website at http://ir.constellationpharma.com/events-and-presentations/events .
  • To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 6275774.
  • MANIFEST is an open-label Phase 2 clinical trial of CPI-0610 in patients with myelofibrosis (MF), a rare cancer of the bone marrow that disrupts the bodys normal production of blood cells.
  • Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.

CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4

Retrieved on: 
Thursday, May 28, 2020
RTT, Clinical medicine, Medicine, Health, Cancer, Myelofibrosis, Targeted therapy

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.

Key Points: 
  • We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.
  • We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need.
  • In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis.
  • We are headquartered in Seattle, Washington.

Sierra Oncology Announces Presentations at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 27, 2020
Nitriles, Morpholines, Myelofibrosis, Janus kinase inhibitor, Momelotinib, Cancer, Forward-looking statement, Clinical medicine, Chemistry

More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.

Key Points: 
  • More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.
  • Sierra has launched MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.
  • All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
  • Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Imago BioSciences To Present Update on Phase 2 results of Bomedemstat (IMG-7289), a Lysine Specific Demethylase-1 (LSD1) Inhibitor for the Treatment of Myelofibrosis (MF)

Retrieved on: 
Tuesday, May 26, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Tyrosine kinases, Janus kinase, Signal transduction, Myelofibrosis, Branches of biology, Thrombocythemia, KDM1A, Cancer, Clinical medicine, Morpholines, Pyrrolidines, Janus kinase inhibitor, Bomedemstat (IMG-7289), Imago BioSciences

Imago is currently conducting a Phase 2 study of bomedemstat in five countries.

Key Points: 
  • Imago is currently conducting a Phase 2 study of bomedemstat in five countries.
  • Bomedemstat is used as monotherapy in patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor.
  • Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes.
  • Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms including myelofibrosis and essential thrombocythemia.

Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings

Retrieved on: 
Wednesday, May 20, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Other Health, Health, Luspatercept, Medicine, Clinical medicine, RTT, Beta thalassemia, Bristol-Myers Squibb, Myelofibrosis, Thalassemia, REBLOZYL® (luspatercept-aamt), Acceleron

REBLOZYL is the first and only U.S. Food and Drug Administration-approved erythroid maturation agent designed to promote red blood cell production through a novel mechanism.

Key Points: 
  • REBLOZYL is the first and only U.S. Food and Drug Administration-approved erythroid maturation agent designed to promote red blood cell production through a novel mechanism.
  • Luspatercept-aamt is being developed to treat anemia in patients with beta-thalassemia, MDS, and myelofibrosis.
  • REBLOZYL is part of the global collaboration between Acceleron and Bristol Myers Squibb.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.